Thiogenesis Therapeutics, Corp. (TSXV:TTI)

Thiogenesis Therapeutics Balance Sheet

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3.85	7.08	6.2	0.06	0.02
Cash & Short-Term Investments	3.85	7.08	6.2	0.06	0.02
Cash Growth	-45.62%	14.21%	9805.77%	225.72%	-
Other Receivables	0.09	0.09	0.06	0.17	0
Receivables	0.09	0.09	0.06	0.17	0
Prepaid Expenses	0.05	0.08	0.04	-	0.03
Total Current Assets	3.98	7.24	6.29	0.23	0.05
Total Assets	3.98	7.24	6.29	0.23	0.05
Accounts Payable	0.56	1.67	0.31	0.68	0.03
Accrued Expenses	-	0.04	-	0	0.01
Short-Term Debt	-	-	-	0.46	0.32
Other Current Liabilities	-	-	-	0.15	-
Total Current Liabilities	0.56	1.71	0.31	1.29	0.36
Total Liabilities	0.56	1.71	0.31	1.29	0.36
Common Stock	16.14	15.01	11.13	1.05	0
Additional Paid-In Capital	-	-	-	0.04	0.62
Retained Earnings	-14.28	-11.14	-6.18	-2.14	-0.93
Comprehensive Income & Other	1.57	1.66	1.03	-0.01	-0
Shareholders' Equity	3.43	5.53	5.98	-1.06	-0.31
Total Liabilities & Equity	3.98	7.24	6.29	0.23	0.05
Total Debt	-	-	-	0.46	0.32
Net Cash (Debt)	3.85	7.08	6.2	-0.4	-0.3
Net Cash Growth	-45.62%	14.21%	-	-	-
Net Cash Per Share	0.08	0.18	0.24	-0.03	-0.03
Filing Date Shares Outstanding	45.76	44.57	38.86	12	10
Total Common Shares Outstanding	45.76	44.57	38.86	12	10
Working Capital	3.43	5.53	5.98	-1.06	-0.31
Book Value Per Share	0.07	0.12	0.15	-0.09	-0.03
Tangible Book Value	3.43	5.53	5.98	-1.06	-0.31
Tangible Book Value Per Share	0.07	0.12	0.15	-0.09	-0.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.